Ad Header



The Pulse of the Pharmaceutical Industry

Sanofi-Regeneron’s Praluent cuts cholesterol in Odyssey trials

Written by: | | Dated: Sunday, June 11th, 2017


France’s Sanofi and partner Regeneron Pharmaceuticals said on Sunday their anti-cholesterol drug Praluent recorded positive results in its first dedicated studies involving patients with diabetes and high cholesterol.

Praluent significantly reduced low-density lipoprotein cholesterol in two phase 3b/4 Odyssey trials, the companies said in a joint statement.


(Reporting by Laurence Frost; Editing by Mark Potter)


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2017 Focus: Manufacturer of the Year, Top 50 Pharma, HBA and more!


Ad Right Bottom

Main Navigation